Prostate Cancer Markers/Surveillance
The changing landscape of prostate cancer diagnosis and management continues to be a major theme, according to Stacy Loeb, MD, MSc.
The 2012 U.S. Preventive Services Task Force recommendation against PSA-based prostate cancer screening and increasing use of active surveillance have led to a shift in the composition of patients undergoing radical prostatectomy, Dr. Loeb said.
“Not surprisingly, active surveillance continues to be a hot topic at this year’s meeting. As more data continue to accrue showing the long-term safety of this management option, there are multiple studies looking into expanding the eligibility criteria. Look out for studies on expanding use of active surveillance in young men and using MRI-targeted biopsy to confirm eligibility,” said Dr. Loeb, assistant professor of urology and population health at New York University School of Medicine, New York.
“There are also several studies on monitoring during active surveillance, including the utility of noninvasive biomarkers and multiparametric MRI,” she added.
New biomarker findings will be another major theme at this year’s meeting.
“Look out for new data on commercially available markers, as well as some new marker tests in the pipeline,” Dr. Loeb said.
Dr. Loeb singled out the following abstracts from this year's meeting:
PD08-01: Prediction of the cancer state to inform a personalized management program for prostate cancer
PD08-07: Molecular Progression of Gleason 6 Prostate Cancer: Tracking of Specific Clones by Image-Guided Biopsy
MP07-01: Validation of a genomic risk classifier to predict prostate cancer death in high risk patients
R. Jeffrey Karnes
MP07-12: Abdominal obesity, altered adipokynes and elevated C-peptide levels are associated with high Gleason score in patients undergoing diagnostic prostate biopsy: Data from prospective registry
Jehonathan H Pinthus
Dr. Loeb also highlighted these abstracts, from Prostate Cancer: Localized: Active Surveillance II:
MP15-02: The Effect of Radical Prostatectomy, External Beam Radiation Therapy, and Active Surveillance on Life Insurance Premiums in Patients with Prostate Cancer
MP15-04: Variation in active surveillance follow-up over two years in diverse urology practices
Amy Luckenbaugh MD
MP15-15: A Retrospective Review of a Large Active Surveillance Cohort in Patients with Prostate Cancer at the Cleveland Clinic
Yaw A. Nyame
MP15-18: Multiparametric MRI outperforms PSA Velocity for Pathologic Progression in Men on Active Surveillance for Prostate Cancer